Shanghai RAAS(002252)2021-10-27 16:00Financial Performance - The company's revenue for Q3 2021 reached ¥1,290,798,229.69, representing a 77.12% increase year-over-year[4] - Net profit attributable to shareholders was ¥485,745,026.42, up 21.78% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥493,141,228.70, reflecting a 31.00% increase year-over-year[4] - Total operating revenue for Q3 2021 reached ¥3,046,522,817.78, a significant increase of 49.5% compared to ¥2,038,065,381.23 in the same period last year[34] - Net profit attributable to the parent company was ¥1,396,174,488.18, up 27.5% from ¥1,095,585,062.50 in Q3 2020[35] - The total comprehensive income for the quarter was ¥1,302,063,087.04, compared to ¥1,143,009,910.62 in Q3 2020, reflecting a growth of 13.9%[36] - Basic and diluted earnings per share were both ¥0.207, an increase from ¥0.173 in the same quarter last year[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥27,674,138,664.36, an increase of 8.55% from the end of the previous year[4] - The company's total liabilities amounted to ¥1,408,825,920.90, an increase of 287.5% from ¥363,735,006.80 year-on-year[32] - The company's current assets reached CNY 6,874,982,757.45, up from CNY 5,012,129,176.45, indicating a significant increase of about 37.2% year-over-year[75] - The company's non-current assets totaled CNY 20,799,155,906.91, an increase from CNY 20,481,669,440.48, reflecting a growth of approximately 1.6%[75] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥1,180,273,101.83, showing a significant increase of 65.02% compared to the previous year[7] - The cash inflow from operating activities for the current period is CNY 3,074,672,754.43, compared to CNY 2,186,506,603.25 in the previous period, representing an increase of approximately 40.5%[38] - The net cash flow from operating activities is CNY 1,180,273,101.83, up from CNY 715,225,594.02 in the previous period, indicating a growth of about 65%[38] - The cash outflow from financing activities totals CNY 554,057,332.69, compared to CNY 68,393,592.20 in the previous period, showing a substantial increase of approximately 707%[39] Shareholder Information - Grifols, S.A. is the largest shareholder, holding 26.20% of shares, equivalent to 1,766,165,808 shares[8] - Kory Tiancheng Investment Holding Co., Ltd. holds 13.18% of shares, totaling 888,731,326 shares, with 888,196,426 shares frozen[8] - RAAS China Limited owns 8.13% of shares, amounting to 548,158,853 shares, all of which are frozen[8] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for over 47.51% of total shares[8] - The company has verified that there are no related party relationships among the top ten shareholders, except for Kory Tiancheng and RAAS China[11] Strategic Agreements and Projects - The company has entered into an exclusive agency agreement with Grifols International, with an estimated total amount of approximately $282.92 million for 2021[13] - The agreement allows Shanghai Laishi and its subsidiaries to act as exclusive distributors for Grifols products in designated areas[13] - The planned total investment for the Southern Headquarters and Inspection Center project is 2 billion RMB, aimed at enhancing production operations and long-term business development[16] - The company has received approval for the production of human albumin and is set to resume sales following the issuance of the relevant production license[18] - The strategic cooperation agreement with Grifols aims to resolve industry competition issues and enhance market share[15] Inventory and Accounts Receivable - The company reported a significant increase in accounts receivable, totaling ¥598,243,053.83, a rise of 48.30% year-over-year, attributed to a substantial increase in sales revenue[6] - The company’s inventory increased by 34.12% due to a rise in imported albumin product stock during the reporting period[6] Legal and Financial Issues - The company has filed a lawsuit seeking repayment of CNY 197,029,490, including principal and late fees, from Shenzhen Xifeng and its controlling parties[28] - The company has fully recognized bad debt losses related to the aforementioned contract dispute, indicating no significant impact on the current year's performance[27] - The court has initiated enforcement proceedings against Shenzhen Xifeng for the outstanding equity transfer payment, with the assessed value of the equity at 50.36 million RMB[69] Research and Development - Research and development expenses for the quarter were ¥77,743,274.40, representing an increase of 12.5% from ¥69,389,351.35 in the previous year[35]